BIOMAT Database Logo BIOMAT Database Logo

Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity. 2007

L J Haddow, and C W Wood, and J G Ainsworth
Coleridge Unit, North Middlesex University Hospital NHS Trust, Silver Street, Edmonton, London N18 1QX, UK.

We aimed to evaluate the reasons for, and timing of, treatment changes in a cohort of treatment-naïve patients initiating non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing highly active antiretroviral therapy (HAART). All 268 patients initiating these regimens between January 1998 and September 2003 were included. Median follow up was 103 weeks. The median baseline CD4 count was 150 cells/microL. Seven patients (3%) died and 155 patients (58%) experienced a change in their HAART regimen. The reasons drugs were discontinued included toxicity in 106 patients (40%), virological failure in 21 (8%), other reasons in 23 (9%) and unknown reasons in five (2%). Fifty-one patients (19%) stopped NRTIs due to peripheral neuropathy, hyperlactataemia, lipoatrophy, lipodystrophy or myelosuppression, and these events were more likely in patients with baseline CD4 count below the median (P = 0.039). The findings in this cohort show that discontinuation of HAART was commonly due to toxicity, especially metabolic or mitochondrial toxicity in those with lower baseline CD4 count.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006113 United Kingdom Country in northwestern Europe including Great Britain and the northern one-sixth of the island of Ireland, located between the North Sea and north Atlantic Ocean. The capital is London. Great Britain,Isle of Man
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

L J Haddow, and C W Wood, and J G Ainsworth
[Antiretroviral therapy. NNRTI (non-nucleoside reverse transcriptase inhibitor)].
March 2000, MMW Fortschritte der Medizin,
L J Haddow, and C W Wood, and J G Ainsworth
Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens.
September 2001, AIDS (London, England),
L J Haddow, and C W Wood, and J G Ainsworth
Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy.
August 2003, AIDS (London, England),
L J Haddow, and C W Wood, and J G Ainsworth
Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy.
January 1998, Antiviral therapy,
L J Haddow, and C W Wood, and J G Ainsworth
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
May 2003, Seminars in liver disease,
L J Haddow, and C W Wood, and J G Ainsworth
Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
January 2007, Antiviral therapy,
L J Haddow, and C W Wood, and J G Ainsworth
Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
March 2009, The Pediatric infectious disease journal,
L J Haddow, and C W Wood, and J G Ainsworth
Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen.
July 2003, AIDS (London, England),
L J Haddow, and C W Wood, and J G Ainsworth
Toxicity of nucleoside-analogue reverse-transcriptase inhibitors.
March 2000, Lancet (London, England),
L J Haddow, and C W Wood, and J G Ainsworth
[Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients].
February 2007, Enfermedades infecciosas y microbiologia clinica,
Copied contents to your clipboard!